Product image of Kanjinti (Trastuzumab) supplied by GNH India

Kanjinti

Active Ingredient:
Trastuzumab
Origin:
EU

Kanjinti (Trastuzumab)

Trastuzumab, the active ingredient in Kanjinti, is a monoclonal antibody presented as an intravenous solution for intravenous use. It targets HER2‑positive cancers and is indicated for patients with metastatic breast cancer, early‑stage breast cancer in the adjuvant setting, and HER2‑positive gastric or gastro‑esophageal junction adenocarcinoma.

GNH India supplies Kanjinti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides cold‑chain logistics for biologic products, ensuring product integrity from manufacturing to delivery.

Manufacturer / TM Owner

Amgen Europe B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Kanjinti is a HER2‑targeted monoclonal antibody used in the treatment of HER2‑positive cancers.

  • HER2‑positive metastatic breast cancer: improves overall survival and delays disease progression.
  • HER2‑positive early breast cancer (adjuvant setting): reduces risk of recurrence after surgery and standard therapy.
  • HER2‑positive gastric or gastro‑esophageal junction adenocarcinoma: enhances response rates and prolongs survival when combined with chemotherapy.

How It Works

  • Trastuzumab binds with high affinity to the extracellular domain IV of the human epidermal growth factor receptor‑2 (HER2) on tumor cells. This binding blocks ligand‑independent HER2 signaling, inhibits downstream pathways such as PI3K/AKT and MAPK, and prevents cell proliferation. Additionally, the antibody flags the cancer cell for immune destruction through antibody‑dependent cellular cytotoxicity (ADCC), recruiting natural killer cells to mediate tumor cell lysis.

Side Effects

Kanjinti may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Infusion‑related reactions (fever, chills, nausea, flushing)
  • Fatigue or weakness
  • Diarrhea or abdominal pain
  • Rash, pruritus or skin erythema
  • Nausea, vomiting or loss of appetite

Serious or Rare Side Effects

  • Cardiac dysfunction, including reduced left ventricular ejection fraction
  • Severe hypersensitivity reactions, such as anaphylaxis or serum sickness
  • Thromboembolic events, including deep‑vein thrombosis or pulmonary embolism
  • Hepatotoxicity with elevated liver enzymes
  • Secondary malignancies (rare)

Precautions & Warnings

When using Kanjinti, several precautions should be observed to ensure patient safety and product integrity.

  • Cardiac assessment: evaluate baseline left ventricular ejection fraction and monitor periodically.
  • Infusion monitoring: administer under medical supervision and watch for signs of hypersensitivity.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks; data are limited.
  • Concomitant cardiotoxic therapies: use caution when combined with anthracyclines or other agents affecting heart function.
  • Immunosuppression: monitor for infections and advise patients to report fever or chills promptly.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Kanjinti can interact with other medicines, and interactions are classified by clinical significance.

Major Interactions (Avoid)

  • Anthracyclines (e.g., doxorubicin): combined use increases risk of cardiac toxicity.
  • Live vaccines: may cause uncontrolled infection due to immune modulation.

Moderate Interactions (Monitor Closely)

  • CYP3A4 inhibitors or inducers: may alter clearance of concomitant drugs metabolized by this pathway.
  • Hormonal therapies (e.g., tamoxifen): potential for additive effects on cardiac function.
  • Anticoagulants: monitor coagulation parameters as trastuzumab may affect platelet function.

Frequently Asked Questions

Kanjinti is a trastuzumab‑based biologic indicated for the treatment of HER2‑positive malignancies, specifically metastatic breast cancer, early‑stage breast cancer in the adjuvant setting, and HER2‑positive gastric or gastro‑esophageal junction adenocarcinoma. It is prescribed by oncologists to target the HER2 receptor and improve clinical outcomes in these patient populations.

Trastuzumab binds to the extracellular domain of the HER2 receptor on cancer cells, blocking downstream signaling pathways that drive cell growth. The binding also flags the tumor cell for immune‑mediated destruction through antibody‑dependent cellular cytotoxicity, recruiting natural killer cells to lyse the HER2‑expressing cells.

The dosing regimen for Kanjinti is determined by the treating physician based on the specific indication, patient weight, cardiac function, and treatment protocol. Clinicians calculate the appropriate infusion volume and schedule, and the product is administered under medical supervision.

Safety data for Kanjinti in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended while receiving trastuzumab because the drug may be excreted in milk.

To order Kanjinti, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Kanjinti is a biosimilar to the reference product Herceptin (trastuzumab). Clinical studies have demonstrated comparable efficacy, safety and immunogenicity profiles. The primary differences lie in manufacturing processes and cost, with biosimilars often offering a more affordable option while meeting the same regulatory standards.

Kanjinti must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Prior to infusion, the solution is allowed to reach room temperature if required by the administration protocol.

Kanjinti is administered as an intravenous infusion in a clinical setting. The initial dose is typically given over 90 minutes, followed by subsequent infusions that may be shortened to 30‑60 minutes depending on patient tolerance and the prescribing protocol.

The most serious adverse events associated with Kanjinti include cardiac dysfunction such as reduced left ventricular ejection fraction, severe hypersensitivity reactions including anaphylaxis, and thromboembolic events like deep‑vein thrombosis or pulmonary embolism. Patients should be monitored regularly for these conditions.

Kanjinti is contraindicated in patients with known hypersensitivity to trastuzumab or any of the formulation components. It should also be avoided in individuals with uncontrolled cardiac disease or a history of severe cardiac failure, and in patients receiving live vaccines due to potential immune interference.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Trastuzumab

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT